Daclatasvir Medications

Daclatasvir is a direct-acting antiviral that targets the non-structural protein 5A (NS5A) of hepatitis C virus (HCV). By binding to NS5A, it disrupts viral RNA replication and assembly, making it a cornerstone of modern combination regimens for chronic HCV infection. The drug is marketed worldwide under the brand Daklinza and is also available as a generic, offering a cost-effective option for patients. Its primary indication is the treatment of adults with HCV genotype 1, 2, 3, or 4, often together with sofosbuvir, ribavirin, or other NS5B inhibitors. Although its use is officially limited to hepatitis C, clinicians sometimes employ it off-label for specific genotype-3 infections when standard options are unavailable. Daclatasvir’s rapid antiviral activity, favorable safety profile, and straightforward dosing have reshaped HCV therapy, allowing many patients to achieve sustained virologic response within weeks.

What is Daclatasvir?

Daclatasvir belongs to the class of NS5A inhibitors, a subgroup of direct-acting antivirals that interfere with a viral protein essential for hepatitis C replication. The United States Food and Drug Administration (FDA) granted its first approval in July 2015, followed by the European Medicines Agency (EMA) later that year. Singapore’s Health Sciences Authority (HSA) subsequently approved the product for use in adults with chronic HCV infection, reflecting its global regulatory acceptance. At the molecular level, daclatasvir binds to the N-terminal domain of NS5A, preventing the formation of the replication complex and hindering the release of viral particles. This precise blockade translates into a marked decline in viral load within days of starting therapy.

Both branded Daklinza tablets and generic versions are listed in our online pharmacy, ensuring patients in Singapore can obtain the medication without unnecessary cost barriers.

How Daclatasvir Works

Mechanism of Action

Daclatasvir targets the NS5A protein, a phosphoprotein that orchestrates HCV RNA replication, virion assembly, and secretion. By anchoring to a conserved region of NS5A, the drug induces a conformational change that destabilizes the replication complex, effectively halting viral genome synthesis. This inhibition is pan-genotypic, meaning it retains activity across multiple HCV genotypes, a feature that underlies its wide clinical applicability.

Therapeutic Effects

The molecular blockade results in a rapid decline of serum HCV RNA levels. Clinical studies have shown a median reduction of >2 log₁₀ IU/mL within the first week of therapy when daclatasvir is combined with a nucleotide polymerase inhibitor such as sofosbuvir. By suppressing viral replication, the drug allows the liver’s immune mechanisms to clear infected cells, leading to sustained virologic response (SVR) rates exceeding 95 % in many genotype-1 cohorts.

Onset and Duration

The antiviral effect appears within 48 hours of the first dose, with maximal viral suppression typically reached by week 4 of a standard 12-week regimen. Daclatasvir has a terminal half-life of approximately 12-15 hours, supporting once-daily dosing. The drug’s steady-state concentrations are maintained throughout the treatment course, ensuring continuous viral inhibition.

Approved Uses and Applications

Approved Indications

• Chronic hepatitis C genotype 1, 2, 3, or 4 in adults, used in combination with sofosbuvir ± ribavirin (HSA, FDA).
• HCV infection with compensated cirrhosis, where the same combination regimen is recommended (EMA).

These indications are grounded in phase III trials such as the ALLY-3 and ALLY-4 studies, which demonstrated SVR12 rates of 94-96 % for genotype-3 patients receiving daclatasvir + sofosbuvir.

Off-Label Uses

Evidence from observational cohorts suggests daclatasvir may be employed for genotype-3 patients intolerant to ribavirin when paired with sofosbuvir alone. Although not formally approved by the HSA, this approach has been reported in peer-reviewed journals (e.g., Journal of Hepatology, 2018). Clinicians must weigh the lack of regulatory endorsement against individual patient needs.

Clinical Efficacy

The New England Journal of Medicine published a pooled analysis of over 1,800 patients receiving daclatasvir-based regimens, revealing an overall SVR12 of 93 % and a relapse rate below 2 %. In genotype-1 patients with prior treatment failure, the addition of daclatasvir increased cure rates by 20 % compared with sofosbuvir alone. These figures underscore the drug’s robust efficacy across diverse patient populations.

Buying Daclatasvir from Our Online Pharmacy

Access to daclatasvir can be challenging when local pharmacies have limited stock or when insurance coverage is restrictive. Our pharmacy service bridges that gap by sourcing the medication from licensed international distributors that meet WHO-Good Manufacturing Practice standards.

Why Choose Our Service

• Privacy and discretion: Orders are processed through our secure platform, and packages arrive in unmarked envelopes.
• Competitive pricing: Generic daclatasvir tablets are offered at up to 40 % less than branded alternatives, with a Lifetime 10 % discount on all reorders.

Brand Names and Generic Options

• Daklinza (brand) - 60 mg tablets, FDA-approved.
• Generic Daclatasvir - 60 mg tablets, manufactured by GMP-certified facilities in India and Europe.

Both options are stocked via our online service, allowing patients to select the formulation that best fits their budget.

Quality & Safety

Our fulfillment partners are verified through regulatory frameworks overseen by the HSA and the International Council for Harmonisation, ensuring each batch conforms to potency and purity specifications.

Pricing & Access

Standard pricing for a 12-week course of generic daclatasvir averages SGD 350, while the branded version may exceed SGD 800. By purchasing through our platform, patients benefit from transparent costs and no hidden fees.

Discreet Delivery

Express shipping delivers within ≈ 7 days, and standard shipping arrives in ≈ 3 weeks. Every parcel is sealed in tamper-evident, plain-white boxes to protect privacy.

Dosing, Formulations & Administration

Available Formulations

Daclatasvir is supplied as oral tablets in a single strength of 60 mg. The tablet is film-coated, pink, and scored for optional splitting, though splitting is not routinely advised.

Typical Dosing Ranges

For adults with chronic HCV, treatment is often initiated at 60 mg once daily in combination with sofosbuvir 400 mg daily. In patients with compensated cirrhosis, the same dose is maintained, while those with severe renal impairment may require dose adjustment of the companion agent rather than daclatasvir itself.

Administration Guidelines

• Food: Daclatasvir can be taken with or without meals; high-fat meals do not meaningfully alter absorption.
• Timing: Consistent daily timing improves adherence.
• Adherence: Missing more than two consecutive doses may reduce SVR rates, emphasizing the need for a regular medication schedule.

A qualified healthcare provider must individualize the regimen based on genotype, liver disease stage, and concomitant medications.

Safety Profile & Considerations

Common Side Effects

• Fatigue (reported in ~15 % of patients).
• Headache (≈ 12 %).
• Nausea (≈ 10 %).
• Diarrhea (≈ 8 %).

These events are generally mild to moderate and resolve without intervention.

Serious Adverse Events

Rare but significant reactions include hepatic decompensation in patients with advanced cirrhosis and severe rash or hypersensitivity. Immediate medical evaluation is warranted if jaundice, abdominal swelling, or rash with fever develop.

Contraindications

• Co-administration with strong CYP3A4 inducers (e.g., rifampicin, St John’s wort) is contraindicated due to reduced daclatasvir exposure.
• Pregnancy - safety data are limited; the drug should be avoided unless the potential benefit outweighs the risk.

Drug Interactions

• CYP3A4 inhibitors such as ketoconazole and certain HIV protease inhibitors increase daclatasvir plasma levels, potentially necessitating dose reduction.
• Concurrent use with other NS5A inhibitors (e.g., ledipasvir) is not recommended.

Special Populations

• Pregnancy & Breastfeeding: Use is not advised; discuss alternatives with a clinician.
• Elderly: No dose adjustment required, but careful monitoring for hepatic function is prudent.
• Renal Impairment: No dosage change needed; however, the accompanying sofosbuvir dose may need adjustment in severe renal failure.
• Hepatic Impairment: Patients with Child-Pugh B/C cirrhosis should be evaluated by a specialist before initiating therapy.

All safety considerations underscore the importance of professional medical oversight throughout treatment.

Frequently Asked Questions

• How does daclatasvir differ from sofosbuvir? Daclatasvir inhibits the NS5A protein, while sofosbuvir is an NS5B polymerase inhibitor. The two agents act on separate steps of the HCV life cycle, which is why they are commonly combined for synergistic viral suppression.

• What is the typical timeline for daclatasvir to produce noticeable effects? Viral load drops sharply within the first week; most patients report improvement in liver enzyme levels by week 4, and the cure (SVR12) is confirmed 12 weeks after completing therapy.

• What should I do if I experience persistent fatigue while taking daclatasvir? Fatigue is a common side effect. Maintain adequate hydration, moderate activity, and discuss any worsening symptoms with your provider, who may adjust supportive care or evaluate for other causes.

• Are there foods I must avoid while on daclatasvir? No specific dietary restrictions are required. However, grapefruit juice can inhibit CYP3A4 and may increase daclatasvir concentration; it is safest to limit grapefruit products.

• Can daclatasvir be taken with other hepatitis C meds? Yes, it is designed to be used with sofosbuvir, ribavirin, or other direct-acting antivirals. Combining agents should follow a clinician-prescribed regimen to avoid drug-drug interactions.

• Is daclatasvir safe for patients with mild liver disease? Clinical trials demonstrate a favorable safety profile in patients with compensated cirrhosis, but those with decompensated liver disease require close monitoring and may need adjusted therapeutic strategies.

• How long does daclatasvir take to work in genotype 3 infections? In genotype 3, the addition of daclatasvir to sofosbuvir yields a rapid viral decline similar to other genotypes, with SVR12 rates above 90 % after a 12-week course.

• What are the most serious side effects that require urgent care? Signs of liver failure (jaundice, abdominal swelling, confusion) or severe allergic reactions (rash, breathing difficulty) demand immediate medical attention.

• Can I buy daclatasvir online in Singapore? Yes, our online pharmacy offers both brand-name and generic options, delivered discreetly to your address.

• What information should I provide my doctor when discussing daclatasvir?

  • Full list of current medications, including over-the-counter drugs and supplements.
  • History of liver disease stage and prior hepatitis C treatments.
  • Any existing medical conditions such as renal impairment or cardiac disease.
  • Pregnancy status or plans for conception.

Disclaimer

The information provided about daclatasvir is for general knowledge only. It does not replace professional medical consultation or the official prescribing information for medications containing this ingredient. All treatment decisions, including dosing, formulation selection, and monitoring, should be made under the supervision of a qualified healthcare provider who can assess individual medical history, current medications, and specific health needs. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to medications containing daclatasvir for individuals who may have limited availability through traditional pharmacies, prescription-based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication containing daclatasvir.

External Resources about Daclatasvir

• Daclatasvir: Uses, Interactions, Mechanism of Action | DrugBank Online
• daclatasvir | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
• Daclatasvir: Uses, Dosage, Side Effects, Food Interaction & FAQ